Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Conditions: Metastatic Malignant Neoplasm in the Brain; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8; St age IV Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 Interventions: Drug: Duvelisib; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | Cutaneous T cell lymphoma | Mycosis Fungoides | Neurology | Research | Sezary Syndrome